,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2014-01-06 04:15:00,The Illinois-based global medical products and services company Baxter International Inc. ( BAX ) announced a nationwide recall of CLINIMIX (Amino Acid in Dextrose) and CLINIMIX E (Amino Acid with Electrolytes in Dextrose with Calcium) injections due to the presence of a harmful matter.,0.03666773810982704,0.8780627846717834,0.08526939153671265,negative,-0.8413950204849243
1,2014-01-06 04:15:00,These injections are used as a caloric component and a protein source for parenteral nutrition.,0.04732415825128555,0.008774688467383385,0.9439011216163635,neutral,0.03854946792125702
2,2014-01-06 04:15:00,"If infused, the harmful matter in the product could lead to blockages of blood vessels, resulting in stroke, heart attack, or damage to other organs such as the kidney or liver.",0.03756675869226456,0.7993790507316589,0.1630542129278183,negative,-0.7618122696876526
3,2014-01-06 04:15:00,"It could also lead to allergic reactions, irritation, and inflammation in tissues and organs.",0.05080005154013634,0.5022004246711731,0.44699952006340027,negative,-0.45140036940574646
4,2014-01-06 04:15:00,"However, the company has not yet received any reports of adverse events associated with the problem till date.",0.01663162186741829,0.17894098162651062,0.804427444934845,neutral,-0.16230936348438263
5,2014-01-06 04:15:00,"The product codes involved in the recall are 2B7729 (lot P287045, exp 06/14), 2B7717 (lot P275883, exp 10/13) and 2B7709 (lot P285122, exp 05/14).",0.012374778278172016,0.02405977062880993,0.963565468788147,neutral,-0.011684992350637913
6,2014-01-06 04:15:00,They were distributed to healthcare centers and distributors in the U.S. between May 2012 and Oct 2013.,0.032014135271310806,0.004924369975924492,0.9630614519119263,neutral,0.027089765295386314
7,2014-01-06 04:15:00,"Recently, BAX announced that it has received U.S. Food and Drug Administration (FDA) approval for its FEIBA (Anti-Inhibitor Coagulant Complex) treatment as well as CE marking in Europe for the VIVIA hemodialysis (HD) system.",0.9276332855224609,0.01401599682867527,0.05835073068737984,positive,0.9136173129081726
8,2014-01-06 04:15:00,"FEIBA is the first and only FDA-approved treatment for routine prophylaxis that controls the frequency of bleeding episodes in hemophilia A or B patients, who have developed inhibitors.",0.21265189349651337,0.008516615256667137,0.7788314819335938,neutral,0.20413528382778168
9,2014-01-06 04:15:00,Inhibitors are antibodies produced by the body's immune system in response to factor replacement treatment.,0.028261825442314148,0.026291994377970695,0.9454461336135864,neutral,0.0019698310643434525
10,2014-01-06 04:15:00,About one-third of previously untreated patients with hemophilia A are at risk of developing inhibitors.,0.0721752718091011,0.5485460162162781,0.37927868962287903,negative,-0.47637075185775757
11,2014-01-06 04:15:00,"VIVIA hemodialysis system is capable of delivering frequent, extended duration, short daily or nocturnal home HD therapy, known as High Dose HD therapy1.",0.06791170686483383,0.005514892283827066,0.9265733957290649,neutral,0.0623968131840229
12,2014-01-06 04:15:00,It is designed with the patient as the primary operator.,0.026241783052682877,0.006269271019846201,0.9674889445304871,neutral,0.019972512498497963
13,2014-01-06 04:15:00,"In November last year, Baxter entered a global licensing agreement with Cell Therapeutics, Inc. ( CTIC ) to jointly develop and commercialize JAK2/FLT3 inhibitor pacritinib that fights against genetic mutations linked to myelofibrosis, leukemia and some tumors.",0.9169021248817444,0.013435891829431057,0.06966202706098557,positive,0.9034662246704102
14,2014-01-06 04:15:00,"As per the agreement, BAX gained the commercialization rights for all indications for pacritinib outside the U.S. while it jointly commercializes with CTIC in the U.S.",0.6920413970947266,0.009707305580377579,0.29825130105018616,positive,0.6823340654373169
15,2014-01-06 04:15:00,"Currently, BAX has a Zacks Rank #4 (Sell).",0.15058663487434387,0.02059260942041874,0.8288208246231079,neutral,0.12999401986598969
16,2014-01-06 04:15:00,"Some better-ranked medical product stocks include Advaxis, Inc. ( ADXS ) and Hill-Rom Holdings, Inc. ( HRC ).",0.5584661364555359,0.02704223431646824,0.41449159383773804,positive,0.5314239263534546
17,2014-01-06 04:15:00,Both of them carry a Zacks Rank #2 (Buy).,0.23823381960391998,0.02332267351448536,0.7384435534477234,neutral,0.21491114795207977
18,2014-01-06 04:15:00,To read this article on Zacks.com click here.,0.017961200326681137,0.01924508437514305,0.9627937078475952,neutral,-0.001283884048461914
19,2014-01-06 04:15:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
